Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521797

SCHEMBL1521797

SCHEMBL1521797

CNc1cc2c(cn1)CN(c1cc(NC(=O)NC3CC3)c(F)cc1C)C(=O)N2C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 3/20 0.37
▸ MAP4K2 Q12851 3/20 0.37
▸ RAF1 P04049 4/20 0.36
▸ BRAF P15056 4/20 0.36
▸ KDR P35968 4/20 0.36
▸ KRAS P01116 3/20 0.36
▸ MAP2K2 P36507 3/20 0.36
▸ MAP2K1 Q02750 3/20 0.36
▸ ARAF P10398 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ FGFR4 P22455 3/20 0.34
▸ FGFR1 P11362 3/20 0.34
▸ TRPV1 Q8NER1 4/20 0.33
▸ BMX P51813 3/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ FGFR3 P22607 2/20 0.33
▸ ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521761 0.89 TAS1R3 (0.35) TNK2MAP4K2RAF1BRAFKDR
SCHEMBL1521647 0.87 RAF1 (0.37) TNK2MAP4K2RAF1BRAFKDR
SCHEMBL1521844 0.85 FGFR1 (0.42) RAF1BRAFKDRKRASMAP2K2
SCHEMBL1521766 0.83 TNK2 (0.42) TNK2MAP4K2BRAFKDRFGFR1
SCHEMBL1521617 0.83 RAF1 (0.37) TNK2MAP4K2RAF1BRAFKDR
SCHEMBL1521700 0.83 RAF1 (0.37) TNK2MAP4K2RAF1BRAFKDR
SCHEMBL1521947 0.82 RAB9A (0.41) TNK2MAP4K2NPC1POLBRAB9A
SCHEMBL1521888 0.82 RAB9A (0.45) RAF1BRAFNPC1RAB9ARET
SCHEMBL1521543 0.82 RAF1 (0.37) TNK2MAP4K2RAF1BRAFKDR
SCHEMBL1521619 0.82 MAPK14 (0.44) TNK2MAP4K2RAF1BRAFKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885RAF1 3/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885RAF1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.